trifarotene 0.05 MG/ML Topical Cream [Aklief]

Verify with CMS →

trifarotene

RxCUI: 2205647

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0.2%
Plan Coverage
8
Plans Covering
T4
Avg Tier
100%
Prior Auth Required

What the CMS Formulary Data Shows for trifarotene 0.05 MG/ML Topical Cream [Aklief]

Per the CMS 2026 Part D formulary file, trifarotene 0.05 MG/ML Topical Cream [Aklief] (RxNorm concept RXCUI 2205647, generic name trifarotene) appears on 1 distinct formulary file spanning 8 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 4, with a cross-plan average of Tier 4.

Real-world access to trifarotene 0.05 MG/ML Topical Cream [Aklief] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 155 Part D beneficiaries filled trifarotene 0.05 MG/ML Topical Cream [Aklief] in 2023, with total plan-and-beneficiary spending of $197,712 and an average per-beneficiary annual cost of $1,275.56. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry trifarotene 0.05 MG/ML Topical Cream [Aklief] today.

Coverage Details

Formularies covering
1
Plans covering
8
Coverage rate
0.2%
Tier range
Tier 4, Non-Preferred
Average tier
Tier 4, Non-Preferred

Restrictions

Prior authorization required
100% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
155
Total spending
$197,712
Avg per beneficiary
$1,275.56

Tier Distribution Across Plans

8 plans
Tier 4, Non-Preferred

Medicare Advantage Plans (MA-PD) Covering trifarotene 0.05 MG/ML Topical Cream [Aklief]

8 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Network Health Select (PPO) NETWORK HEALTH INSURANCE CORPORATION T4 Yes $0 WI
Network Health Go (PPO) NETWORK HEALTH INSURANCE CORPORATION T4 Yes $0 WI
Network Health Anywhere (PPO) NETWORK HEALTH INSURANCE CORPORATION T4 Yes $0 WI
Network Health Choice (PPO) NETWORK HEALTH INSURANCE CORPORATION T4 Yes $0 WI
Network Health Zero (PPO) NETWORK HEALTH INSURANCE CORPORATION T4 Yes $0 WI
Network Health Cares (PPO D-SNP) NETWORK HEALTH INSURANCE CORPORATION T4 Yes $21.10 WI
Network Health PlusRx (PPO) NETWORK HEALTH INSURANCE CORPORATION T4 Yes $38.60 WI
Network Health PremierRx (PPO) NETWORK HEALTH INSURANCE CORPORATION T4 Yes $92.80 WI

Frequently Asked Questions

Is trifarotene 0.05 MG/ML Topical Cream [Aklief] covered by Medicare Part D?

Yes, trifarotene 0.05 MG/ML Topical Cream [Aklief] is covered by 8 Medicare Part D plans (0.2% of all Part D formularies).

What tier is trifarotene 0.05 MG/ML Topical Cream [Aklief] on Medicare Part D plans?

trifarotene 0.05 MG/ML Topical Cream [Aklief] averages Tier 4 across Part D plans, ranging from Tier 4 to Tier 4.

Does trifarotene 0.05 MG/ML Topical Cream [Aklief] require prior authorization?

100% of Part D formularies require prior authorization for trifarotene 0.05 MG/ML Topical Cream [Aklief]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on trifarotene 0.05 MG/ML Topical Cream [Aklief]?

In 2023, total Medicare Part D spending on trifarotene 0.05 MG/ML Topical Cream [Aklief] was $197,712, covering 155 beneficiaries. The average spend per beneficiary was $1,275.56.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial